ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new interview, Patrick Mizer, chief technology officer at Ledger Run, explains how the shift from competing for patients to competing for high-performing sites has made payment reliability an operational brand. Sites now prioritize which trials to join based on sponsor track records for timely payments and financial predictability, a factor materially influencing enrollment and site quality.
• In a new Q&A, Stella K. Vnook, PhD, CEO and executive chair of Kaida BioPharma and founder and CEO of Aviva Ventures, discussed how declining NIH funding, late-stage pharma acquisition focus, and global trial speed are forcing early-stage biotechs to move faster and deploy capital more strategically on inflection point data. Commercialization input must now inform clinical decisions at indication selection and trial design rather than after Phase II, a shift that demands fundamentally different planning disciplines.
• Hanmi Pharm licensed HM17321 to Genentech for development, regulatory, and commercial milestones totaling up to $2.3 billion, with a $190 million upfront payment and tiered royalties on future sales. HM17321 is a Ucn2 analog pursuing a non-GLP-1 mechanism targeting body composition through selective fat reduction while preserving muscle mass; Hanmi is completing Phase I while Genentech assumes development from Phase II onward, with preclinical data showing efficacy both as monotherapy and in combination with incretin-based treatments.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.